No More Pandemics

Hiroshi Kase, PhD, joined Kyowa Hakko Kogyo Co., Ltd. (Japan) in 1966, and served as researcher, as Director of the Pharmaceutical Research Institute and as Global Project Leader. As a representative accomplishment, he was involved in the discovery and development of adenosine A2A antagonist KW-6002 (istradefylline) for a new Parkinson's Disease drug with a novel action mechanism, leading to success in its launch in Japan and the United States. He is the author and editor of "Adenosine Receptor and Parkinson's Disease" (2000).Yoshikazu G. Mikawa, MD, PhD joined Dr Sydney Brenner's Molecular Genetics Unit in Cambridge, UK, in 1989 and collaborated in the USA until 2005. His work propelled DNA technologies, particularly in the next-generation sequencing. He developed a bacteriophage lambda peptide display system and genetically modified bacteria for ligand-receptor binding analysis. He was Principal Scientific Officer at Population Genetics Technologies Ltd, UK (2005-2013). He co-founded Nemesis Bioscience Ltd (UK) in 2014, focusing on cutting-edge technologies addressing antimicrobial resistance.